# Pediatric Hypothalamic Obesity

> **NCT00076362** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Sandostatin LAR

## Key facts

- **NCT ID:** NCT00076362
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-07
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2011-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00076362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00076362, "Pediatric Hypothalamic Obesity". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00076362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*